Beijing Immunochina Pharmaceuticals

Beijing Immunochina Pharmaceuticals (北恒生物, also going by Imviva Biotech) is a Beijing-based cell therapy company focused on universal (off-the-shelf) CAR-T products — one BlueRun Ventures piece describes it as a "leading company in universal cell therapy" . Its backers include Qiming Venture Partners and BlueRun Ventures . Its pipeline updates, as tracked in Qiming's weekly portfolio notes through 2025-2026, include FDA IND clearance for its CD7-targeting universal CAR-T CTD402 (early 2025), which later received FDA rare pediatric disease designation (September 2025) ; Phase 1 data for its CD19-targeting RD06-03 in relapsed/refractory B-ALL, presented at ASCO 2025 ; and, as of June 2026, a further FDA IND approval for a new candidate, CTA313 . elsewhere's corpus covers the company mainly through these investor update digests, so details like founding date and funding history aren't covered.